<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="drug-table.xslt"?><drug name = "pembrolizumab inj VIAL">
<dose><value>2</value>
</dose>
<route><value>IV</value>
</route>
<strength><value>50 mg</value>
</strength>
<frequency><value>EVERY 3 WEEKS</value>
</frequency>
<instruction><value>Administer dose diluted on 50 mL sodium chloride 0.9% over 30 minutes.</value>
</instruction>
<volume></volume>
<units><value>mg/kg</value>
</units>
<Population><value>ADULT</value>
</Population>
<IndicationPRN></IndicationPRN>
<AdditionalNotes><value>There are no dose reductions for pembrolizumab. Doses are either delayed or discontinued for toxicity.</value>
</AdditionalNotes>
<BackgroundInformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=8661</value>
</BackgroundInformation>
<PRNInformation></PRNInformation>
<AHSFormularyStatus><value>Formulary with Restrictions.</value>
</AHSFormularyStatus>
<AHFSName><value>Antineoplastic Agents</value>
</AHFSName>
<HighAlert><value>YES</value>
</HighAlert>
</drug>